Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab

Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab

A novel combination of capecitabine, oxaliplatin, and bevacizumab was evaluated in colorectal cancer patients enrolled in a phase II clinical trial. In this retrospective analysis, plasma samples from patients receiving capecitabine, oxaliplatin, and bevacizumab were analyzed to investigate biomarke...

Full description

Bibliographic Details
Main Authors:	Liu, Yingmiao, Starr, Mark D, Bulusu, Anuradha, Pang, Herbert, Wong, Nan Soon, Honeycutt, Wanda, Amara, Anthony, Hurwitz, Herbert I, Nixon, Andrew B
Format:	Online
Language:	English
Published:	Blackwell Publishing Ltd 2013
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639662/

Similar Items

Effects of the combination of TRC105 and bevacizumab on endothelial cell biology
by: Liu, Yingmiao, et al.
Published: (2014)

Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis
by: Buchler, Tomas, et al.
Published: (2014)

Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer
by: Dellas, Kathrin, et al.
Published: (2013)

Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205
by: Hoehler, T, et al.
Published: (2013)

Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer
by: Munemoto, Yoshinori, et al.
Published: (2015)

Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer
by: Bazarbashi, Shouki, et al.
Published: (2015)

Tissue MicroRNAs as Predictors of Outcome in Patients with Metastatic Colorectal Cancer Treated with First Line Capecitabine and Oxaliplatin with or without Bevacizumab
by: Boisen, Mogens K., et al.
Published: (2014)

First-line bevacizumab and capecitabine–oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study
by: Feliu, J, et al.
Published: (2014)

Combination of Capecitabine and Oxaliplatin is an Effective Treatment Option for Advanced Neuroendocrine Tumors
by: Ferrarotto, Renata, et al.
Published: (2013)

Combination of capecitabine and oxaliplatin is an effective treatment option for advanced neuroendocrine tumors
by: Renata Ferrarotto, et al.
Published: (2013-09-01)

Economic comparison of capecitabine + oxaliplatin and 5-fluorouracil + oxaliplatin in the adjuvant treatment of colon cancer
by: Aitini, Enrico, et al.
Published: (2012)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial
by: Madi, A, et al.
Published: (2012)

A Muti-center, Randomized Phase II Study of Oxaliplatin and S-1 versus Capecitabine and Oxaliplatin in Patients with Metastatic Colorectal Cancer
by: Kim, Jung Han, et al.
Published: (2015)

Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer
by: Liu, Yingmiao, et al.
Published: (2014)

Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer
by: Pander, Jan, et al.
Published: (2015)

Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study
by: Jackson, Christopher GCA, et al.
Published: (2014)

A case of advanced intrahepatic cholangiocarcinoma accidentally, but successfully, treated with capecitabine plus oxaliplatin (CAPOX) therapy combined with bevacizumab: a case report
by: Uji, Masahito, et al.
Published: (2016)

GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study
by: Pietrantonio, Filippo, et al.
Published: (2016)

Efficacy of Bevacizumab-Capecitabine in Combination for the First-Line Treatment of Metastatic Breast Cancer
by: Dyar, Stephen, et al.
Published: (2011)

A phase I study of ABT-510 plus bevacizumab in advanced solid tumors
by: Uronis, Hope E, et al.
Published: (2013)

Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model
by: Iwai, Toshiki, et al.
Published: (2016)

A Phase II Study of Sequential Capecitabine Plus Oxaliplatin Followed by Docetaxel Plus Capecitabine in Patients With Unresectable Gastric Adenocarcinoma: The TCOG 3211 Clinical Trial
by: Chen, Ming-Huang, et al.
Published: (2016)

Factors Influencing Clinicians' Choice of Adjuvant S-1 versus Capecitabine plus Oxaliplatin after Curative Gastrectomy in Patients with Gastric Cancer
by: Lee, Ha Yeon, et al.
Published: (2016)

Predictive role of hand–foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer
by: Zielinski, Christoph, et al.
Published: (2016)

Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies
by: Mammoliti, S., et al.
Published: (2011)

The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer
by: Hansen, Torben Frøstrup, et al.
Published: (2012)

Efficacy and Safety of Docetaxel Plus Oxaliplatin and Capecitabine in the First Line Treatment of Advanced Gastric Adenocarcinoma
by: Liu, Ying, et al.
Published: (2013)

Lethal cardiotoxicity, steatohepatitis, chronic pancreatitis, and acute enteritis induced by capecitabine and oxaliplatin in a 36-year-old woman
by: Gurzu, Simona, et al.
Published: (2013)

Capecitabine and Oxaliplatin (XELOX) for the Treatment of Patients with Metastatic Gastric Cancer and Severe Liver Dysfunction
by: Hwang, Seung Jae, et al.
Published: (2006)

Prospective clinical study of capecitabine plus oxaliplatin concurrent chemoradiotherapy after radical resection of rectal cancer
by: Wanghua Chen, et al.
Published: (2018-08-01)

Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer
by: Kim, Seung Tae, et al.
Published: (2016)

Evaluation of Outcome and Tolerability of Combination Chemotherapy with Capecitabine and Oxaliplatin as First Line Therapy in Advanced Gastric Cancer
by: Mashhadi, Mohammad Ali, et al.
Published: (2016)

A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract
by: Graham, J. S., et al.
Published: (2016)

The impact of chemosensory and food-related changes in patients with advanced oesophagogastric cancer treated with capecitabine and oxaliplatin: a qualitative study
by: de Vries, Yfke C., et al.
Published: (2016)

Complete Response of Isolated Para-aortic Lymph Node Recurrence from Rectosigmoid Cancer Treated by Chemoradiation Therapy with Capecitabine/Oxaliplatin plus Bevacizumab: A Case Report
by: Miyazawa, Tomonori, et al.
Published: (2012)

Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab
by: Mitsuhashi, Atsushi, et al.
Published: (2015)

Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer
by: Mahner, Sven, et al.
Published: (2015)

Leptin’s Pro-Angiogenic Signature in Breast Cancer
by: Gonzalez-Perez, Ruben Rene, et al.
Published: (2013)

The Use of Calcium and Magnesium to Prevent Neurotoxicity in Patients Receiving Oxaliplatin
by: Martyn, Karon, et al.
Published: (2015)

Interim analysis of postoperative chemoradiotherapy with capecitabine and oxaliplatin versus capecitabine alone for pathological stage II and III rectal cancer: a randomized multicenter phase III trial
by: Feng, Yan-Ru, et al.
Published: (2016)